


Original Research

Obinutuzumab activates Fc γ RI more potently than other anti-CD20 antibodies in chronic lymphocytic leukemia (CLL)

Shlomo Elias , Shira Kahlon, Rebecca Kotzur, Noah Kaynan & Ofer Mandelboim 

Article: e1428158 | Received 19 Dec 2017, Accepted 09 Jan 2018, Accepted author version posted online: 16 Jan 2018, Published online: 12 Feb 2018

 Download citation  <https://doi.org/10.1080/2162402X.2018.1428158>



 Full Article

 Figures & data

 References

 Supplemental

 Citations

 Metrics

 Licensing

 PDF

© 2018 The Author(s). Published with license by Taylor & Francis Group, LLC© Shlomo Elias, Shira Kahlon, Rebecca Kotzur, Noah Kaynan and Ofer Mandelboim

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (<http://creativecommons.org/licenses/by-nc-nd/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.

People also read

Article

Choice of costimulatory domains and of cytokines deter